Yilmaz, IsmetElmas, Muammer2024-08-042024-08-0420101300-6045https://hdl.handle.net/11616/104290The aim of this study was to evaluate the bioequivalence (BE) of two medicinal products of enrofloxacin, which have been also marketed as 10% injectable solution in Turkey, after the intramuscular injection (IM) at a single dose of 2.5 mg/kg of BW in the heifers. The present study was performed on healthy 6 Swiss-Brown (12-18 months and 340-400 kg BW) heifers. This study was carried out on the based a single dose cross-over design. Blood samples were taken into sterilized tubes just before, and 10(th), 20(th), 30(th), 45(th), 60(th) and 90(th) min. and 2(th), 3(th), 4(th), 6(th), 8(th), 12(th) and 24(th) h following injections. The plasma concentrations of enrofloxacin (ENR) were measured by high performance liquid chromatography (HPLC) following the extraction process. The plasma concentration-time curves for each animals showed that both products distributed according two-compartment open model. The basic pharmacokinetic parameters at this study were only the AUC(0-24) and AUC(total) were statistically significant (P<0.05) before logarithmic (log) transformation. Log transformed the AUC(0-24), AUC(total) and C(max) parameters and observed t(max) were used in BE evaluation. Minimum, maximum and mean AUC(0-24) AUC(total) and C(max) for A and B products were found in the acceptable ranges (70-143%). For the t(max) value log transformation has not been done and that were determined within the limits 80-125%. As a result; it is concluded that both products could be used instead of each other as an inter-changeable drugs.eninfo:eu-repo/semantics/closedAccessBioequivalenceEnrofloxacinHeiferArticle163377382WOS:000278340800004Q4